858 Therapeutics

8five8tx.com

858 Therapeutics is a clinical-stage biotechnology company focused on developing small molecule drugs targeting novel therapeutic areas in oncology and immunology. Founded by an experienced management team, the company is dedicated to discovering innovative therapies for patients suffering from cancer and immune diseases. Its lead program, a PARG inhibitor, is currently in early clinical development, showcasing the company's commitment to addressing unmet medical needs. Headquartered in San Diego, CA, 858 Therapeutics is positioned within a vibrant biotech ecosystem, leveraging its expertise to advance its drug discovery pipeline and establish a strong market presence.